Anebulo Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Richie Cunningham
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 18.3% |
| CEO tenure | 1.3yrs |
| CEO ownership | n/a |
| Management average tenure | 2.1yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$8m |
| Jun 30 2024 | US$2m | US$333k | -US$8m |
Compensation vs Market: Richie's total compensation ($USD1.82M) is above average for companies of similar size in the German market ($USD456.62K).
Compensation vs Earnings: Insufficient data to compare Richie's compensation with company performance.
CEO
Richie Cunningham (53 yo)
1.3yrs
Tenure
US$1,819,383
Compensation
Mr. Richard Anthony Cunningham, also known as Richie, is Chief Executive Officer and Director of Anebulo Pharmaceuticals, Inc. since October 2023. He served as Chief Executive Officer and Director at Tyme...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 4.8yrs | US$83.11k | 46.27% € 17.8m | |
| CEO & Director | 1.3yrs | US$1.82m | no data | |
| Principal Accounting Officer | 1.4yrs | US$194.25k | no data | |
| Chief Scientific Officer | 2.8yrs | US$612.15k | 0% € 0 |
2.1yrs
Average Tenure
53.5yo
Average Age
Experienced Management: 214's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 4.8yrs | US$83.11k | 46.27% € 17.8m | |
| CEO & Director | 1.3yrs | US$1.82m | no data | |
| Independent Director | 1.3yrs | US$124.53k | 0% € 0 | |
| Lead Independent Director | 4yrs | US$68.24k | 0% € 0 | |
| Independent Director | 3.8yrs | US$76.87k | 0% € 0 | |
| Independent Director | 3.9yrs | US$83.24k | 0% € 0 | |
| Independent Director | 2.3yrs | US$67.26k | 0% € 0 | |
| Independent Director | 4.7yrs | US$66.87k | 17.95% € 6.9m | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data |
4.0yrs
Average Tenure
52yo
Average Age
Experienced Board: 214's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 13:50 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anebulo Pharmaceuticals, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |